Organ Transplant Rejection Medication Market Size Report, 2032

Organ Transplant Rejection Medication Market - By Drug Class (Calcineurin Inhibitor, Antibodies, Antiproliferative Agent), Transplant Type (Kidney, Liver, Heart), Distribution Channel (Hospital, Retail Pharmacies), Global Forecast, 2023-2032

Report Content

Chapter 1&nbsp;&nbsp;&nbsp;Methodology &amp; Scope

1.1&nbsp;&nbsp;&nbsp; Market definition

1.2&nbsp;&nbsp;&nbsp; Base estimates &amp; calculations

1.3&nbsp;&nbsp;&nbsp; Forecast calculation

1.4&nbsp;&nbsp;&nbsp; Covid-19 impact analysis at global level

1.5&nbsp;&nbsp;&nbsp; Data validation

1.6&nbsp;&nbsp;&nbsp; Data sources

1.6.1&nbsp;&nbsp;&nbsp; Secondary

1.6.1.1&nbsp;&nbsp;&nbsp;Paid sources

1.6.1.2&nbsp;&nbsp;&nbsp;Public sources

1.6.2&nbsp;&nbsp;&nbsp; Primary

Chapter 2&nbsp;&nbsp;&nbsp;Executive Summary

2.1&nbsp;&nbsp;&nbsp; Organ transplant rejection medication industry 360&ordm; synopsis, 2018 &ndash; 2032 (USD Million)

2.1.1&nbsp;&nbsp;&nbsp; Business trends

2.1.2&nbsp;&nbsp;&nbsp; Region trends

2.1.3&nbsp;&nbsp;&nbsp; Drug class trends

2.1.4&nbsp;&nbsp;&nbsp; Transplant type trends

2.1.5&nbsp;&nbsp;&nbsp; Distribution channel trends

Chapter 3&nbsp;&nbsp;&nbsp;Organ Transplant Rejection Medication Market Insights

3.1&nbsp;&nbsp;&nbsp; Industry landscape, 2018 &ndash; 2032 (USD Million)

3.2&nbsp;&nbsp;&nbsp; Industry impact forces

3.2.1&nbsp;&nbsp;&nbsp; Growth drivers

3.2.1.1&nbsp;&nbsp;&nbsp;Increasing organ transplant procedures due to chronic diseases

3.2.1.2&nbsp;&nbsp;&nbsp;Technological advancements in organ transplantation and tissue engineering

3.2.2&nbsp;&nbsp;&nbsp; Industry pitfalls &amp; challenges

3.2.2.1&nbsp;&nbsp;&nbsp;High cost of organ transplantation procedures

3.2.2.2&nbsp;&nbsp;&nbsp;Low availability of organs for transplantation

3.3&nbsp;&nbsp;&nbsp; Growth potential analysis

3.3.1&nbsp;&nbsp;&nbsp; By drug class

3.3.2&nbsp;&nbsp;&nbsp; By transplant type

3.3.3&nbsp;&nbsp;&nbsp; By distribution channel

3.4&nbsp;&nbsp;&nbsp; COVID-19 impact analysis

3.5&nbsp;&nbsp;&nbsp; Regulatory landscape

3.6&nbsp;&nbsp;&nbsp; Porter&rsquo;s analysis

3.7&nbsp;&nbsp;&nbsp; PESTEL analysis

Chapter 4&nbsp;&nbsp;&nbsp;Competitive Landscape, 2022

4.1&nbsp;&nbsp;&nbsp; Introduction

4.2&nbsp;&nbsp;&nbsp; Company matrix analysis, 2022

4.3&nbsp;&nbsp;&nbsp; Competitive positioning matrix, 2022

4.4&nbsp;&nbsp;&nbsp; Strategic dashboard, 2022

Chapter 5&nbsp;&nbsp;&nbsp;Organ Transplant Rejection Medication Market Estimates and Forecast, By Drug Class, 2018 - 2032 (USD Million)

5.1&nbsp;&nbsp;&nbsp; Key trends, by drug class

5.2&nbsp;&nbsp;&nbsp; Calcineurin inhibitors

5.3&nbsp;&nbsp;&nbsp; Antibodies

5.4&nbsp;&nbsp;&nbsp; Antiproliferative agents

5.5&nbsp;&nbsp;&nbsp; mTOR inhibitor

5.6&nbsp;&nbsp;&nbsp; Steroids

Chapter 6&nbsp;&nbsp;&nbsp;Organ Transplant Rejection Medication Market Estimates and Forecast, By Transplant Type, 2018 - 2032 (USD Million)

6.1&nbsp;&nbsp;&nbsp; Key trends, by transplant type

6.2&nbsp;&nbsp;&nbsp; Kidney

6.3&nbsp;&nbsp;&nbsp; Liver

6.4&nbsp;&nbsp;&nbsp; Heart

6.5&nbsp;&nbsp;&nbsp; Lung

6.6&nbsp;&nbsp;&nbsp; Pancreas

6.7&nbsp;&nbsp;&nbsp; Other transplant types

Chapter 7&nbsp;&nbsp;&nbsp;Organ Transplant Rejection Medication Market Estimates and Forecast, By Distribution Channel, 2018 - 2032 (USD Million)

7.1&nbsp;&nbsp;&nbsp; Key trends, by distribution channel

7.2&nbsp;&nbsp;&nbsp; Hospital pharmacies

7.3&nbsp;&nbsp;&nbsp; Retail pharmacies

7.4&nbsp;&nbsp;&nbsp; Online pharmacies

Chapter 8&nbsp;&nbsp;&nbsp;Organ Transplant Rejection Medication Market Estimates and Forecast, By Region, 2018 - 2032 (USD Million)

8.1&nbsp;&nbsp;&nbsp; Key trends, by region

8.2&nbsp;&nbsp;&nbsp; North America

8.2.1&nbsp;&nbsp;&nbsp; U.S.

8.2.2&nbsp;&nbsp;&nbsp; Canada

8.3&nbsp;&nbsp;&nbsp; Europe

8.3.1&nbsp;&nbsp;&nbsp; Germany

8.3.2&nbsp;&nbsp;&nbsp; UK

8.3.3&nbsp;&nbsp;&nbsp; France

8.3.4&nbsp;&nbsp;&nbsp; Spain

8.3.5&nbsp;&nbsp;&nbsp; Italy

8.3.6&nbsp;&nbsp;&nbsp; Switzerland

8.3.7&nbsp;&nbsp;&nbsp; Rest of Europe

8.4&nbsp;&nbsp;&nbsp; Asia Pacific

8.4.1&nbsp;&nbsp;&nbsp; China

8.4.2&nbsp;&nbsp;&nbsp; Japan

8.4.3&nbsp;&nbsp;&nbsp; India

8.4.4&nbsp;&nbsp;&nbsp; Australia

8.4.5&nbsp;&nbsp;&nbsp; South Korea

8.4.6&nbsp;&nbsp;&nbsp; Rest of Asia Pacific

8.5&nbsp;&nbsp;&nbsp; Latin America

8.5.1&nbsp;&nbsp;&nbsp; Brazil

8.5.2&nbsp;&nbsp;&nbsp; Mexico

8.5.3&nbsp;&nbsp;&nbsp; Rest of Latin America

8.6&nbsp;&nbsp;&nbsp; Middle East &amp; Africa

8.6.1&nbsp;&nbsp;&nbsp; South Africa

8.6.2&nbsp;&nbsp;&nbsp; Saudi Arabia

8.6.3&nbsp;&nbsp;&nbsp; Rest of Middle East &amp; Africa

Chapter 9&nbsp;&nbsp;&nbsp;Company Profiles

9.1&nbsp;&nbsp;&nbsp; Astellas Pharma Inc.

9.2&nbsp;&nbsp;&nbsp; Sanofi

9.3&nbsp;&nbsp;&nbsp; Bristol-Myers Squibb Company

9.4&nbsp;&nbsp;&nbsp; Novartis AG

9.5&nbsp;&nbsp;&nbsp; F. Hoffmann-La Roche Ltd

9.6&nbsp;&nbsp;&nbsp; Accord Healthcare Ltd

9.7&nbsp;&nbsp;&nbsp; Viatris, Inc.

9.8&nbsp;&nbsp;&nbsp; Dr. Reddy&#39;s Laboratories Ltd

9.9&nbsp;&nbsp;&nbsp; Veloxis Pharmaceuticals A/S

9.10&nbsp;&nbsp;&nbsp; GlaxoSmithKline plc 
&nbsp;

Organ Transplant Rejection Medication Market

Get a free sample of this report